CA3247129A1 - SERPINE PEPTIDES AND THEIR METHODS OF USE - Google Patents

SERPINE PEPTIDES AND THEIR METHODS OF USE

Info

Publication number
CA3247129A1
CA3247129A1 CA3247129A CA3247129A CA3247129A1 CA 3247129 A1 CA3247129 A1 CA 3247129A1 CA 3247129 A CA3247129 A CA 3247129A CA 3247129 A CA3247129 A CA 3247129A CA 3247129 A1 CA3247129 A1 CA 3247129A1
Authority
CA
Canada
Prior art keywords
seq
peptide
serpin
disease
serpin peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3247129A
Other languages
English (en)
French (fr)
Inventor
Dana AUSTIN
Cohava Gelber
Original Assignee
SERPIN PHARMA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SERPIN PHARMA LLC filed Critical SERPIN PHARMA LLC
Publication of CA3247129A1 publication Critical patent/CA3247129A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3247129A 2022-01-05 2022-12-30 SERPINE PEPTIDES AND THEIR METHODS OF USE Pending CA3247129A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263266444P 2022-01-05 2022-01-05
US63/266,444 2022-01-05
PCT/US2022/082669 WO2023133078A2 (en) 2022-01-05 2022-12-30 Serpin peptides and methods of using the same

Publications (1)

Publication Number Publication Date
CA3247129A1 true CA3247129A1 (en) 2023-07-13

Family

ID=87074167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3247129A Pending CA3247129A1 (en) 2022-01-05 2022-12-30 SERPINE PEPTIDES AND THEIR METHODS OF USE

Country Status (8)

Country Link
US (2) US20250161419A1 (cg-RX-API-DMAC7.html)
EP (1) EP4460322A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503607A (cg-RX-API-DMAC7.html)
CN (1) CN118804758A (cg-RX-API-DMAC7.html)
AU (1) AU2022431253A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247129A1 (cg-RX-API-DMAC7.html)
IL (1) IL314135A (cg-RX-API-DMAC7.html)
WO (1) WO2023133078A2 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016317726B2 (en) * 2015-08-28 2022-05-26 Serpin Pharma, Llc Methods for treatment of diseases
EP3402572B1 (en) * 2016-01-13 2022-03-16 Children's Hospital Medical Center Compositions and methods for treating allergic inflammatory conditions
CA3134610A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
US20240342293A1 (en) * 2019-10-10 2024-10-17 Yale University Engineered antibodies as molecular degraders through cellular receptors
WO2021092050A1 (en) * 2019-11-04 2021-05-14 Azitra Inc Compositions and methods for treatment or prevention of skin diseases and disorders with lekti
EP4789728A2 (en) * 2020-07-06 2026-08-12 Serpin Pharma, LLC Peptides and methods of using the same
BR112023016690A2 (pt) * 2021-02-22 2023-11-14 Univ Yale Degradadores bifuncionais direcionados e métodos usando os mesmos

Also Published As

Publication number Publication date
JP2025503607A (ja) 2025-02-04
EP4460322A2 (en) 2024-11-13
US20250161419A1 (en) 2025-05-22
CN118804758A (zh) 2024-10-18
WO2023133078A3 (en) 2023-08-17
EP4460322A4 (en) 2026-02-25
WO2023133078A2 (en) 2023-07-13
AU2022431253A1 (en) 2024-07-25
US20230406906A1 (en) 2023-12-21
IL314135A (en) 2024-09-01

Similar Documents

Publication Publication Date Title
Xu et al. Methamphetamine exposure triggers apoptosis and autophagy in neuronal cells by activating the C/EBPβ‐related signaling pathway
Luo et al. Astragaloside IV enhances diabetic wound healing involving upregulation of alternatively activated macrophages
Liu et al. Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via the inhibition of inducible nitric oxide synthase expression and the TGF-β/Smad signaling pathway
Elsherbiny et al. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy
Wu et al. Recombinant adiponectin peptide promotes neuronal survival after intracerebral haemorrhage by suppressing mitochondrial and ATF4‐CHOP apoptosis pathways in diabetic mice via Smad3 signalling inhibition
Chen et al. Carbon monoxide ameliorates acetaminophen‐induced liver injury by increasing hepatic HO‐1 and Parkin expression
US11779630B2 (en) Peptides and methods of using the same
Ji et al. SS-31 inhibits mtDNA–cGAS–STING signaling to improve POCD by activating mitophagy in aged mice
Chen et al. Asiatic acid alleviates cisplatin-induced renal fibrosis in tumor-bearing mice by improving the TFEB-mediated autophagy-lysosome pathway
Yang et al. Resolvin D2 activates anti-inflammatory microglia via restoring autophagy flux and alleviate neuropathic pain following spinal cord injury in rats
Tamai et al. Caveolae in mesangial cells and caveolin expression in mesangial proliferative glomerulonephritis
Lin et al. Peroxisome proliferator-activator receptor γ and psoriasis, molecular and cellular biochemistry
Xu et al. The NLRP3 activation in infiltrating macrophages contributes to corneal fibrosis by inducing TGF-β1 expression in the corneal epithelium
Yang et al. Effect of Acer tegmentosum bark on atopic dermatitis-like skin lesions in NC/Nga mice
US20190216901A1 (en) Acth prophylactic treatment of renal disorders
Cao et al. Intracellular and extracellular Cyclophilin a promote cardiac fibrosis through TGF-β signaling in response to angiotensin Ⅱ
US20250161419A1 (en) Serpin peptides and methods of using the same
Lee et al. Protective Effect of Delta-Like 1 Homolog against muscular atrophy in a mouse model
HK40118659A (en) Serpin peptides and methods of using the same
KR20230034167A (ko) Kai1 폴리펩타이드를 포함하는 간 섬유화 억제용 약학 조성물 및 이의 용도
HK40121727A (en) Serpin peptide derivatives and methods of using the same
EP4514838A1 (en) Serpin peptide derivatives and methods of using the same
Chen et al. Etomidate protects against homocysteine-induced blood-brain barrier disruption via upregulation of Krüppel-like factor 2
KR102115557B1 (ko) 폐 섬유증의 예방 또는 치료용 약학적 조성물
US20170016005A1 (en) Pharmaceutical composition and method for reducing scar formation

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240705

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241210

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241210

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241211

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241211

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250304

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT - OTHER THAN 5.09.01/02/03 DETERMINED NOT COMPLIANT

Effective date: 20250304

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260417

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260504

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20260504

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260504

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260601